Brevets

·      Johannes L, Goud B, Tartour E, Friedman WH. 1997. Chimeric polypeptide comprising the fragment B of Shiga toxin and peptides of therapeutic interest. Filed in France on July 18, 1997; worldwide extension on July 17, 1999 (WO99/03881); delivered in the US, Europe, Hong-Kong, Japan; licensed to Select Therapeutic Inc (1998-2001), ShigaMediX (2005-2010), STxB Pharma Technologies Inc (2012-2014); option agreement in siRNA field with Cenix Biosciences (2010-2013); option agreement with Remora Partners (2015-ongoing).

·      Green A, Johannes L, Goud B, Tartour E, Fridman WH. 1998. Verotoxin B-subunit for immunization. Patent EP 99 923 063,4; delivered in Europe; licensed to Select Therapeutic Inc (1998-2001), ShigaMediX (2005-2010), STxB Pharma Technologies Inc (2012-2014); option agreement in siRNA field with Cenix Biosciences (2010-2013); option agreement with Remora Partners (2015-ongoing).

·      Johannes L, Goud B, Fridman WH, Tartour E, Florent JC. 2001. Universal carrier for targeting molecules to Gb3 receptor expressing cells. European patent filed on February 1st, 2001; worldwide extension (WO 02/060937); delivered in the US, Europe, Japan; licensed to Select Therapeutic Inc (2001), ShigaMediX (2005-2010), STxB Pharma Technologies Inc (2012-2014); option agreement in siRNA field with Cenix Biosciences (2010-2013); option agreement with Remora Partners (2015-ongoing).

·      Johannes L, Florent JC, Grierson D, Maillard P, Robine S, and Roger J. 2002. Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to Gb3 expressing tumors. European patent filed on August 2, 2002 (EP 02 291 965.5); delivered in the US, Europe, Japan; licensed to STxB Pharma Technologies Inc (2012-2014); option agreement in siRNA field with Cenix Biosciences (2010-2013).

·      Tartour E, Johannes L, Fridman WH, Freyburger L, Adotevi O, and Vingert V. 2006. Compositions using the B-subunit of Shiga toxin as a means of stimulating NKT cells. European patent filed on December 28, 2006 (EP 06 292 066.5); licensed to ShigaMediX (2006-2010), STxB Pharma Technologies Inc (2012-2014); option agreement with Remora Partners (2015-ongoing).

·      Johannes L, Florent JC, Schmidt F, El Alaoui A, Decaudin D, and Robine S. 2007. Shiga toxin B-subunit/Chemotherapeutics conjugates. US patent filed on December 18, 2007 (US 11 958 576); licensed to ShigaMediX (2007-2010), STxB Pharma Technologies Inc (2012-2014).

·      Gillet D, Barbier J, Johannes L, Stechmann B, and Bai SK. 2009. Inhibitors of the Shiga toxin trafficking through the retrograde pathway. European patent (EP 2296757 A2, WO2009153665A2).

·      Tartour E, Johannes L. 2011. Compositions having means for targeting at least one antigen to dendritic cells. European patent (EP11305959.6, WO2013014128A1); licensed to STxB Pharma Technologies Inc (2012-2014); option agreement with Remora Partners (2015-ongoing).

·      Gillet D, Barbier J, Johannes L, Cintrat JC, and Noël R. 2012. Nouveaux composés ayant une activité protectrice vis-à-vis de l’action de toxines au mode d’action intracellulaire. European patent filed on October 19, 2012 (EP12306297, US9540356B2).

·      Johannes L. 2012. Conjugates of the B subunit of Shiga toxin for use as contrasting agents for imaging and therapy. European Patent EP12306524.5, WO2014086942A1.

·      Johannes L. 2012. Conjugates of the B subunit of Shiga toxin for anticancer therapies. European Patent EP12306521.1; option agreement with Remora Partners (2015-ongoing).

·      Johannes L, Deutsch E, and Tartour E. 2014. Combined vaccination / radiotherapy for cancer treatment. European Patent EP20150000507 / WO2016134838A1.

·      Johannes L, and Murarsu T. 2017. Peptides, peptide library screening and uses for research and biomedical applications. European Patent EP17305454.5 filed on April 20, 2017, and PCT/EP2018/056311, filed on March 13, 2018; under contract with OGD2 Pharma (2017-ongoing).